首页> 中文期刊> 《中国生化药物杂志》 >通心络胶囊联合参麦注射液对急性失代偿心力衰竭患者左室射血分数、hs-CRP、BNP及QTcd的影响

通心络胶囊联合参麦注射液对急性失代偿心力衰竭患者左室射血分数、hs-CRP、BNP及QTcd的影响

         

摘要

目的 观察通心络胶囊联合参麦注射液对急性失代偿心力衰竭患者左室射血分数(LVEF)、高敏C反应蛋白(hs-CRP)、利钠肽(BNP)及QT间期离散度(QTcd)的影响.方法 选取2014年5月~2015年4月山东大学第二医院收治的82例急性失代偿心力衰竭患者,根据抽签法分为观察组和对照组,每组41例.对照组给予基础治疗和参麦注射液治疗,观察组在对照组治疗基础上联合通心络胶囊进行治疗.分析2组患者临床疗效和不良反应,比较2组治疗前后血压、心率、LVEF、hs-CRP、BNP、QTcd指标变化.结果 治疗后,观察组总有效率显著高于对照组[92.68%(38/41)vs 60.97%(25/41)](P<0.05).观察组的心率水平明显低于对照组(P<0.05),2组患者血压水平比较差异无统计学意义.观察组的LVEF水平显著高于对照组[(45.98±4.57)%vs(39.07±3.12)%](P<0.05),BNP、hs-CRP、QTcd水平显著低于对照组[(2432.12±114.32)ng/L、(17.32±1.87)mg/L、(34.76±3.02)ms vs(3565.87±174.76)ng/L、(14.08±1.23)mg/L、(38.45±3.86)ms](P<0.05).2组均未发现不良反应情况.结论 通心络胶囊联合参麦注射液治疗急性失代偿心力衰竭患者,能有效增加左室射血分数,降低hs-CRP、BNP及QTcd,临床疗效良好,安全性高.%Objective To study the effects of Tongxinluo capsule and Shen Mai injection in treatment of patients with acute myocardial infarction and its effects on level of left ventricular ejection fraction (LVEF),high sensitive C-reactive protein (hs-CRP),natriuretic peptide (BNP) and QT in acute decompensated heart failure ( QTcd) .Methods 82 patients with acute decompensated heart failure were selected in our hospital from May 2014 to April 2015, those patiens were divided into observation group and control group according to the method of lottery, 41 cases each group.The control group was treated with basic treatment and Huangxin injection, and the obsevation group was treated with Tongxinluo capsule on the basis of the control group.The changes of blood pressure, heart rate, LVEF, hs-CRP, BNP and QTcd were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the observation group was significantly higher than the control group [92.68% (38/41) vs 60.97%(25/41)](P<0.05).The heart rate of the observation group was significantly lower than the control group (P<0.05), but the blood pressure level of the two groups had no significant difference.The levels of BNP, hs-CRP and QTcd in the observation group were significantly higher than the control group [(45.98 ±4.57)% vs(39.07 ±3.12)%](P<0.05) L, BNP, hs-CRP and QTcd were significantly lower than the control group [(2432.12 ± 114.32)ng/L,(17.32 ±1.87) mg/L, (34.76 ±3.02) ms vs (3565.87 ±174.76) ng/L, (14.08 ±1.23) mg/L,(38.45 ±3.86)].Adverse reactions were not observed in the observation group and the control group.Conclusion Tongxinluo capsule combined with Shen Mai injection can effectively increase the left ventricular ejection fraction and reduce hs-CRP, BNP and QTcd in patients with acute decompensated heart failure.The clinical curative effect is good and the safety is high.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号